Hormone related problems (Endocrinopathies and osteoporosis) Vincenzo de Sanctis Ferrara.
|
|
- Adela Andrews
- 5 years ago
- Views:
Transcription
1 Hormone related problems (Endocrinopathies and osteoporosis) Vincenzo de Sanctis Ferrara 6 th EUROPEAN SYMPOSIUM ON RARE ANAEMIAS 1 st Dutch-Belgian meeting for patients and health professionals 21 st - 22 nd November 2015 Amsterdam - The Netherlands
2 This talk is applicable for: Definite Thalassemia s x - Sickle cell disease x - Membrane disorders (e.g. sferocytosis) - - Enzym defects (e.g. PKD, G6PD) - - PNH - - Other forms of hemolytic disease - - Probable
3 SCD (25 pts.) NTDT (60 pts.) Beta thalassemia major ( > 1000 pts. and 700 BMT pts.) Personal experience
4 Disclosures Company name Quisisana Hospital Research support Employee Consultant Stockholder Speakers bureau Advisory board Other None - Pediatrics and Adolescent Medicine
5 Outline Brief presentation of : 1.Prevalence of endocrine complications in TM -TI and SCD 2. Emerging problems in TM and TI 3.Osteopenia/osteoporosis in TM -TI and SCD 4.Conclusions
6 The prevalence of growth retardation and endocrine complications Endocrinopathies present in 3,174 TM patients around the world
7 THALASSEMIA Endocrine complications (% in both sexes) Cyprus (n = 435) North America (n = 262) Italy (n = 1,861) Country Iran (n = 220) Turkey (n = 252) Oman (n=144) Hypogonadism DM/IGT / /11.8 Short stature/ghd / (GHD) (GHD) Primary hypothyroidism Hypoparathyroidism DM, diabetes mellitus; GHD, growth hormone deficiency; IGT, impaired glucose tolerance. 1. Cunningham MJ, et al. Blood. 2004;104: De Sanctis V, et al. Clin Endocrinol.1995;42: Fung E, et al. Br J Haematol. 2006;135: Kattamis C, et al. Semin Hematol.1995;32: Thalassaemia International Federation Toumba M, et al. Ped Endocrinol Rev. 2007;5: Vichinsky E, et al. Am J Hematol. 2005;80: Yaprak I, et al. Klinik Arastirma. 2002;12:
8 AGE OF APPEARANCE OF ENDOCRINE COMPLICATIONS IN THALASSEMIA More than half of patients with TM, even in paediatric cohorts, have at least 1 endocrinopathy. (Early assessment) The frequency of endocrine organ damage related to iron overload increased with age (median age 36 years: 67% had hypogonadism, 14% hypothyroidism
9 NTDT encompasses a wide clinical spectrum 20 parameters were selected for inclusion in the disease severity scoring system. An additional six parameters, largely related to growth and development, were selected specifically for pediatric patients ( 16years of age). Eur J Intern Med.2015 Nov 3.. [Epub ahead of print] Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia. Cappellini MD et al.
10 50 TI PATIENTS (21 males) ; yrs. ( mean 28.7 yr)
11 In the following years..
12 SCD SCD NTDT Beta thalassemia major
13 Growth failure and endocrine complications in SCD compared to TM Clinical evidence suggests that SCD patients are less likely to have endocrine complications
14 Subjects divided into paediatric (<21 years of age) and adult sub groups (>21 years) SUMMARY For the paediatric subgroup: Thal subjects were more likely to have growth failure, hypogonadism and diabetes compared with Tx-SCD (41.3% vs. 5.3%, 34.2% vs. 5.8%, and 10.9% vs.0.9% respectively). There were no significant differences between Tx-SCD and non-tx-scd for any of the endocrinopathies For adults: Thal subjects were more likely than Tx-SCD subjects to have growth failure (29.2% vs. 9.5%; p:0.001), hypogonadism (40.6% vs. 2.4%,p: < 0.001), hypothyroidism (12.9% vs. 1.2%, P: 0.003) and diabetes (13.7% vs. 3.5%;p:0.02). Neither recent serum ferritin levels nor LIC by biopsy was a significant predictor of endocrinopathy. There were no significant differences between Tx-SCD and non-tx-scd subjects.
15 The evidences Despite iron overload, endocrinopathy was not increased in Tx-SCD versus non-tx-scd, suggesting that the underlying disease may modulate iron-related endocrine injury. However, because transfusion duration remained a significant predictor of endocrinopathy, these data should be confirmed in SCD subjects that have been chronically transfused for longer periods of time. The protective factors in SCD
16 The protective factors in SCD Malondialdehyde levels are higher in thalassaemia compared with SCD. PROTECTIVE FACTORS In contrast, several inflammatory markers appeared higher in SCD. This inflammation in SCD may generate increased levels of γ- tocopherol, leading to decreased tissue peroxidation and injury.
17 The causes: in addition to iron overload Anaemia Chronic liver diseases Iron toxicity Ineffective erytropoiesis Nutricional deficiences Episodes of intravascular sickling, vaso-occlusion and infarction Short Stature/ Endocrine Complications/ Reduced BMD
18 Associated factors Overall, the prevalence of growth, endocrine disorders and reduced BMD is affected also by other factors such as: age of first transfusion, haemoglobin level attained before blood transfusion, degree and type of chelation, compliance with chelation, age of first exposure to chelation therapy, association with other endocrine complications and genotype.
19 Splenectomy
20 Emerging problems Malignancies/Microprolactinoma Hypoadrenalism Osteoporosis and fractures Emerging Complications HPT and intracranial calcifications Vit. D deficiency Growth hormone deficiency in adults Testicular microcalcinosis Central hypothyroidism
21 Bones in thalassemias and SCD In SCD patients an high prevalence (76%) of osteopenia in young adults: 50% spine, 31% hip.
22 Prevalence of reduced BMD in NTDT compared to TM
23 Factors contributing to reduced BMD
24 Prevalence of fractures in β- thalassemia Prevalence of fractures according to age and fracture site
25
26 In summary: from the literature Despite similar iron burden, transfused patients with Thal are at greater risk for fracture than subjects with SCD. In multivariate analysis, the significant predictors of fracture prevalence were Thal diagnosis (Odds Ratio: 2.3; ; 95%CI), male gender (OR: 2.6; ), hypothyroidism (OR: 3.3; ) and age (OR: 1.1; ). Transfused subjects with SCD had no greater risk of fracture compared to nontransfused SCD. Though ethnic differences in fracture risk cannot be ignored, endocrinopathy is rare in TxSCD which may also provide some protection from fracture.
27 Osteoporosis: Prevention & Treatment
28
29 Denosumab RANKL/OPG Balance Drives Osteoclast Activity Is a fully human monoclonal antibody to the receptor activator of nuclear factor kappab ligand (RANKL). Inhibits osteoclast formation Decreases bone resorption Increases bone mineral density (BMD)
30 Results and side effects Results: Denosumab therapy for a year Significant increase in BMD of : 9.2% (95% CI, 8.2 to 10.1) at the lumbar spine and 6.0% (95% CI, 5.2 to 6.7) at the total hip. Side effects in our patients Pain in the back and/or extremities 4/30 Nausea 3/30. Asymptomatic hypocalcaemia in 2/30
31
32 Final considerations
33 Anemia,growth and IGF-1
34 Anemia and spermatogenesis Eighteen young adults with SCD on packed cell transfusion (10 on TTx, and eight on ETx after previous stroke during their childhood period. Patients were on iron chelation therapy using oral deferasirox in the last 3-4 years (30-40 mg/kg body weight once a day). Top-up transfusion (TTx); exchange transfusion (ETx) After PCTx significant increase of Hb from 8.5 ± 1.2 g/dl to 10.5 ± 0.4 g/dl was associated with increased concentrations of T (from 12.3 ± 1.2 nmol/l to 14.2 ± 1.2 nmol/l), LH (from 4.4 ± 0.9 U/L to 5.7 ± 0.85 U/L), and FSH (from 5.4 ± 1.46 U/L to 6.6 ± 1.8 U/L). Total sperm count increased significantly from 87.4 ± 24.6 million/ml to 146 ± 51 million/ml and rapid progressive sperm motility (RPM) increased from 29.3 ± 8.75 million/ml to 67.4 ± 29.1 million/ml. Blood transfusions packed red cell transfusion (PCTx)
35 Chelation therapy and endocrine complications: The personal experience
36 The major difficulties reported by doctors : A personal survey
37 Bulgaria- Cyprus - Egypt - Jordan Greece India Indonesia- Iran Malaysia- Oman - Qatar Romania- Russia Saudi Arabia Turkey- UK- USA
38
Effects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis
Effects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis Mohamed Yassin 1 Ashraf T. Soliman2, Mohamed O. Abdelrahman3, Vincenzo De Sanctis 4 Departments of, 1 Hematology 2Pediatric
More informationENDOCRINE DISORDERS IN THALASSEMIA MAJOR: QUALITY OF LIFE BEYOND SURVIVAL
ENDOCRINE DISORDERS IN THALASSEMIA MAJOR: QUALITY OF LIFE BEYOND SURVIVAL 1,2 Carmen Barbu, 1,2 Alice Albu, 3 Larisa Nitu, 3 Daniela Voicu, 1,3 Florentina Vladareanu, 2 Suzana Florea and 1,2 Simona Fica
More informationPart I. Pathophysiology and management of Thalassemia Intermedia. M. Domenica Cappellini Fondazione IRCCS Policlinico University of Milan
Pathophysiology and management of Thalassemia Intermedia M. Domenica Cappellini Fondazione IRCCS Policlinico University of Milan 4th European Symposium on Rare Anaemias 3rd Bulgarian Symposium on Thalassaemia
More informationHow far one should go with iron chelation in thalassemia? Is iron deficiency indicated?
How far one should go with iron chelation in thalassemia? Is iron deficiency indicated? DR. KALLISTHENI FARMAKI THALASSAEMIA UNIT GENERAL HOSPITAL OF CORINTH, GREECE VASILI BERDOUKAS PEDIATRIC HEMATOLOGIST
More informationDr Banu Kaya Consultant Haematologist Barts Health NHS Trust Royal London Hospital, London, UK SICKLE CELL AND THALASSAEMIA OVERVIEW
Dr Banu Kaya Consultant Haematologist Barts Health NHS Trust Royal London Hospital, London, UK SICKLE CELL AND THALASSAEMIA OVERVIEW Objectives Gain awareness of haemoglobinopathy inheritance, pathophysiology
More informationTHALASSEMIA AND COMPREHENSIVE CARE
1 THALASSEMIA AND COMPREHENSIVE CARE Melanie Kirby MBBS, FRCP (C), Hospital for Sick Children, Toronto Associate Professor of Paediatrics, University of Toronto. Objectives 2 By the end of this presentation,
More informationLa terapia dell osteoporosi nel soggetto talassemico Therapy of Thalassemia Major-Induced Osteoporosis
La terapia dell osteoporosi nel soggetto talassemico Therapy of Thalassemia Major-Induced Osteoporosis Ashraf Soliman, Vincenzo De Sanctis Mohamed A Yassin, Institutes Departments of Pediatric Endocrinology,
More informationSMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
More informationAn overview of Thalassaemias and Complications
An overview of Thalassaemias and Complications Haemoglobin Haemoglobin is the most abundant protein in blood, and exists as three main types in normal adults: HbA ( ) - 97% HbA 2 ( ) - 2.5% HbF ( ) - 0.5%
More informationDisclosures of: Emanuele Angelucci
Company name Novartis Disclosures of: Emanuele Angelucci Research support Employee Consultant Stockholder Speakers bureau Advisory board Chair of TELESTO pro Other EBMT 2012 Educational Session Haemoglobinopathy
More informationResearch Article Beta-Thalassaemia Intermedia: Evaluation of Endocrine and Bone Complications
BioMed Research International, Article ID 174581, 5 pages http://dx.doi.org/10.1155/2014/174581 Research Article Beta-Thalassaemia Intermedia: Evaluation of Endocrine and Bone Complications M. Baldini,
More informationCounselling and prenatal diagnosis. Antonis Kattamis, Greece
Counselling and prenatal diagnosis Antonis Kattamis, Greece Epidemiology of Hemoglobinopathies 7% of world population carriers of hemoglobinopathies 500.000 newborns annually affected 300.000 : Thalassemias
More informationNon-transfusion-dependent thalassemia (NTDT) Bor-Sheng Ko, M.D. Ph.D. Meng-Yao Lu, M.D. National Taiwan University Hospital
Non-transfusion-dependent thalassemia (NTDT) Bor-Sheng Ko, M.D. Ph.D. Meng-Yao Lu, M.D. National Taiwan University Hospital Introduction Transfusion dependency in thalassemia Transfusions seldom required
More informationBeta-thalassemia:clinical findings,molecular defects and genotype/phenotype relationships
Beta-thalassemia:clinical findings,molecular defects and genotype/phenotype relationships Maria Domenica Cappellini Fondazione Ca Granda Policlinico IRCCS University of Milan Disclosure Member of Advisory
More informationPrevalence of fractures among Thais with thalassaemia syndromes
817 Original Article Prevalence of fractures among Thais with thalassaemia syndromes Sutipornpalangkul W, Janechetsadatham Y, Siritanaratkul N, Harnroongroj T Department of Orthopaedic Surgery, Faculty
More informationPrevalence of Osteoporosis among Thalassemia Patients from Zafar Adult Thalassemia Clinic, Iran
ORIGINAL ARTICLE IJBC 2014;6(3): 143-148 Prevalence of Osteoporosis among Thalassemia Patients from Zafar Adult Thalassemia Clinic, Iran Hashemieh M 1, Azarkeivan A 2 *, Radfar M 3, Saneifard H 4, Hosseini-Zijoud
More informationEndocrine Function in Thalassemia Intermedia
International journal of Biomedical science REVIEW ARTICLE Endocrine Function in Thalassemia Intermedia H. Karamifar 1, M. Karimi 2, G. H. Amirhakimi 1, M. Badiei 1 1 Division of Endocrinology and Metabolism,
More informationEndocrine Function in Thalassemia Intermedia
International journal of Biomedical science Endocrine Function in Thalassemia Intermedia Karamifar H 1, Karimi M 2, Amirhakimi GH 1, Badiei M 1 1 Division of Endocrinology and Metabolism, Department of
More informationIn adults, the predominant Hb (HbA) molecule has four chains: two α and two β chains. In thalassemias, the synthesis of either the α or the β chains
Thalassaemias Thalassemia Thalassemia is an inherited autosomal recessive blood disease. Associated with absence or reduction in a or b globin chains. Reduced synthesis of one of the globin chains can
More informationGeneral insights and current management of Thalassemia Intermedia. Maria Domenica Cappellini
Palermo 16 Settembre 217 General insights and current management of Thalassemia Intermedia Maria Domenica Cappellini Rare Disease Center Dept of Internal Medicine Fondazione IRCCS Cà Granda Policlinico
More informationNuovi Approcci alla Ferrochelazione
Il Deficit di PKD 1 patient day Nuovi Approcci alla rrochelazione M. Domenica Cappellini Fondazione Ca Granda Policlinico Università di Milano Milano May 16 2015 Genetic and acquired iron overload Genetic
More informationStandards of Care in Thalassemia. What is Thalassemia?
Standards of Care in Thalassemia Thalassemia Support group Thomas D Coates, MD Childrens Hospital Los Angeles What is Thalassemia? Thalassemia is an inherited disorder due to a DNA mutation that causes
More informationThalassaemia and other haemoglobinopathies
EXECUTIVE BOARD EB118/5 118th Session 11 May 2006 Provisional agenda item 5.2 Thalassaemia and other haemoglobinopathies Report by the Secretariat PREVALENCE OF HAEMOGLOBINOPATHIES 1. Haemoglobinopathies,
More informationOriginal Article INTRODUCTION:
Original Article International Journal of Dental and Health Sciences Volume 03,Issue 03 EFFECT OF HEMOGLOBIN AND FERRITIN OF SERUM CONCENTRATIONS ON THE DENSITY OF JAWBONE THAT INTENDED FOR DENTAL IMPLANT
More informationOriginal Article Endocrine Dysfunctions in Iron Overload in Patients with Major Thalassemia
Original Article Endocrine Dysfunctions in Iron Overload in Patients with Major Thalassemia Downloaded from ijpho.ssu.ac.ir at 3:18 IRDT on Wednesday July 25th 2018 Hashemi A MD 1, Hashemian Z MD 1, Ordooei
More informationReview Article Iran J Ped Hematol Oncol. 2016, Vol 7.No 1, 57-62
Review Article Iran J Ped Hematol Oncol. 2016, Vol 7.No 1, 57-62 Thalassemia intermedia; folic acid and vitamin B12 supplementation. What we know and what is needed? Mehran Karimi MD 1,*, Nader Cohan PhD
More informationProf Sanath P Lamabadusuriya
Prof Sanath P Lamabadusuriya What is Thalassaemia? It is the commonest inherited variety of anaemia It is the commonest haemoglobinopathy in Sri Lanka Of all the different types, Beta-Thalassaemia major
More informationTHE EFFECT OF HIGH CALORIC DIET ON NUTRITIONAL PARAMETERS OF CHILDREN WITH THALASSAEMIA MAJOR.
THE EFFECT OF HIGH CALORIC DIET ON NUTRITIONAL PARAMETERS OF CHILDREN WITH THALASSAEMIA MAJOR. Ashraf T Soliman MD, PhD Professor of Pediatrics and Endocrinology Thalassemia Ht 102 cm HtSDS = -5.98 Transfusion
More informationLuspatercept Increases Hemoglobin, Decreases Transfusion Burden, and Improves Patient-Reported Outcomes in Adults with Beta-Thalassemia
Luspatercept Increases Hemoglobin, Decreases Transfusion Burden, and Improves Patient-Reported Outcomes in Adults with Beta-Thalassemia Antonio G. Piga, MD 1, Immacolata Tartaglione, MD 2, Rita Gamberini,
More informationNon-transfusion-dependent thalassemia (NTDT) Bor-Sheng Ko, M.D. Ph.D. Meng-Yao Lu, M.D. National Taiwan University Hospital
Non-transfusion-dependent thalassemia (NTDT) Bor-Sheng Ko, M.D. Ph.D. Meng-Yao Lu, M.D. National Taiwan University Hospital Introduction Spectrum of thalassemia: Resulting from unbalanced α/β chains α-thalassemias
More informationParathyroid Functions in Thalassemia Major Patients
Open Access Annals of Clinical Endocrinology and Metabolism Research Article Parathyroid Functions in Thalassemia Major Patients Ayfer Gözü Pirinççioğlu 1 *, Deniz Gökalp 2 and Murat Söker 1 1 Department
More informationOriginal Article Assessment of Hypothyroidism in Children with Beta-Thalassemia Major in North Eastern Iran
Original Article Assessment of Hypothyroidism in Children with Beta-Thalassemia Major in North Eastern Iran Hashemizadeh H MSc 1, Noori R MSc 2 Downloaded from ijpho.ssu.ac.ir at 18:46 IRDT on Wednesday
More informationManagement and Clinical Outcome of Children with Transfusion-Dependent Thalassaemia in Hospital Tuanku Ja'afar Seremban
ORIGINAL ARTICLE Management and Clinical Outcome of Children with Transfusion-Dependent Thalassaemia in Hospital Tuanku Ja'afar Seremban AINA MARIANA Abdul Manaf, MMed(Peds)*; Song Hong YAP, MRCPCH** *Department
More informationOriginal Article Thyroid Function Assessment With Beta-Thalassemia Major Pak Armed Forces Med J 2016; 66(6):809-13
Open Access Original Article Thyroid Function Assessment With Beta-Thalassemia Major Pak Armed Forces Med J 2016; 66(6):809-13 ASSESSMENT OF STATUS OF THYROID FUNCTIONS IN PATIENTS OF β THALASSEMIA MAJOR,
More informationHow to Write a Life Care Plan for a Child with Hemoglobinopathy
How to Write a Life Care Plan for a Child with Hemoglobinopathy Tamar Fleischer, BSN, MSN, CNLCP & Mona Yudkoff, RN, MPH, CRRN, CNLCP BalaCare Solutions March 2018 St. Peterburg, Florida What is Hemoglobinopathy?
More informationCongenital Dyserythropoietic anemias: where we are
Congenital Dyserythropoietic anemias: where we are Achille Iolascon Department of Molecular Medicine and Medical Biotechnology University Federico II of Naples, Italy achille.iolascon@unina.it 6 th EUROPEAN
More informationBeta Thalassemia Frequency in Bahrain: A Ten Year Study. Shaikha Salim Al-Arrayed, MB,ChB, DHCG, PhD*
Bahrain Medical Bulletin, Vol. 2, No. 2, June 200 Beta Thalassemia Frequency in Bahrain: A Ten Year Study Shaikha Salim Al-Arrayed, MB,ChB, DHCG, PhD* Background: Sickle-cell disease and Thalassanemia
More informationSurvival and Disease Complication of Thalassemia Major: Experience of 14 Years at King Abdulaziz University Hospital, Jeddah, KSA
JKAU: Med. Sci., Vol. 17 No. 1, pp: 19-28 (2010 A.D. / 1431 A.H.) DOI: 10.4197/Med. 17-1.3 Survival and Disease Complication of Thalassemia Major: Experience of 14 Years at King Abdulaziz University Hospital,
More informationHemoglobinopathies NORMAL HEMOGLOBINS
Hemoglobinopathies Millicent Sutton MD October 28, 2005 NORMAL HEMOGLOBINS Consist of 2 alpha chains and 2 non alpha chains Hb A = α2β2 Hb F= α 2γ2 Hb A2 = α2δ2 1 Hemoglobin Variants Altered the conformational
More informationMultidisciplinary care. Michael Angastiniotis
Multidisciplinary care Michael Angastiniotis Pathopysiology of β-thalassaemia Thalassaemia syndromes are inherited haemoglobin disorders caused by defective and imbalanced globin production Excess free
More informationPartnership between sickle cell nurse and families in outpatient clinic
Partnership between sickle cell nurse and families in outpatient clinic Ngalula Mujinga Malou Nurse (sickle cell disease) University Children Hospital Queen Fabiola (HUDERF)(Belgium) 6 th EUROPEAN SYMPOSIUM
More informationThalassemia Maria Luz Uy del Rosario, M.D.
Thalassemia Maria Luz Uy del Rosario, M.D. Philippine Society of Hematology and Blood Transfusion Philippine Society of Pediatric Oncology What is Thalassemia Hereditary Hemoglobin disorder Hemolytic anemia
More information1 Pediatric and Adolescent Clinic, Quisisana Hospital, Ferrara, Italy, 2 Department of Pediatrics, Division of
Selected Highlights of the VIII International Symposium of Clinicians for Endocrinopathies in Thalassemia and Adolescent Medicine (ICET-A ) on Growth, Puberty and Endocrine Complications in Thalassaemia.
More informationInterleukin-1ß and Interleukin-6 Genetic Polymorphisms and Sickle Cell Disease: An Egyptian Study
Interleukin-1ß and Interleukin-6 Genetic Polymorphisms and Sickle Cell Disease: An Egyptian Study MONA EL-GHAMRAWY, MD, PROFESSOR OF PEDIATRICS & PEDIATRIC HEMATOLOGY, CAIRO UNIVERSITY melghamrawy95@gmail.com
More information1st International Working Group on Thalassemia:
1st International Working Group on Thalassemia: Effectiveness and safety of 10 different regimens for controlling iron overloading in Thalassemia Major CAMPUS OF HEMATOLOGY "Franco e Piera Cutino" A.O.R.
More informationIron Overload in Sickle Cell Disease Review of Cause and Treatment
Iron Overload in Sickle Cell Disease Review of Cause and Treatment Susan M. Carson RN, MSN, CPNP Nurse Practitioner III Hematology Program Children s Hospital Los Angeles Objectives Describe the effect
More informationNon-malignant hematologic disorders associated arthropathies: hemoglobinopathy-associated musculoskeletal manifestations, hemophilia
Non-malignant hematologic disorders associated arthropathies: hemoglobinopathy-associated musculoskeletal manifestations, hemophilia HAEMOGLOBINOPATHIES = inherited disorders of globin divided into: Thalassaemia
More informationDependance on chronic transfusion
Dependance on chronic transfusion Pr Saliou Diop Hematology Blood transfusion Dakar- Sénégal diop@cnts-dakar.sn Introduction Chronic transfusion: Regular use of blood transfusion in patients with chronic
More informationHealth Maintenance and Education for Children and Adults
Health Maintenance and Education for Children and Adults Richard Ward, MSc, MRCP, FRCPath Director, Red Blood Cell Disorders Program, UHN Assistant Professor, Hematology, University of Toronto Chair, Canadian
More informationCongenital Haemoglobinopathies
Congenital Haemoglobinopathies L. DEDEKEN, MD H O P I T A L U N I V E R S I T A I R E D E S E N F A N T S R E I N E F A B I O L A U N I V E R S I T E L I B R E DE B R U X E L L E S Red Blood Cell Disorders
More informationIntroduction: Is it time to revisit classification of Thalassemia Syndromes?
1st International Working Group on Thalassemia: Introduction: Is it time to revisit classification of Thalassemia Syndromes? CAMPUS OF HEMATOLOGY "Franco e Piera Cutino" A.O.R. "Villa Sofia - V. Cervello"
More informationTransfusion Practices and Creation of a Registry for Patients with Sickle Cell Disease within the Atlanta Sickle Cell Consortium
Transfusion Practices and Creation of a Registry for Patients with Sickle Cell Disease within the Atlanta Sickle Cell Consortium Annie Winkler MD Assistant Professor, Emory University Department of Pathology
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationCOPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017
COPD-Related Musculoskeletal Disease Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017 A 60-year old man with COPD comes into your office for a routine office visit. He is a former
More informationCOHEM Barcellona 2012 Hemoglobinopathies debate
COHEM Barcellona 2012 Hemoglobinopathies debate September 8, 2012: h. 10:30-12:00 Hall: A Is it justified to perform BMT in hemoglobinopathies using unrelated and/or partially mismatched donors? HSCT indication
More informationResearch Article Prevalence and Risk Factors for Complications in Patients with Nontransfusion Dependent Alpha- and Beta-Thalassemia
Anemia Volume 2015, Article ID 793025, 7 pages http://dx.doi.org/10.1155/2015/793025 Research Article Prevalence and Risk Factors for Complications in Patients with Nontransfusion Dependent Alpha- and
More information21th -22th November 2015 Amsterdam The Netherlands
6 th EUROPEAN SYMPOSIUM ON RARE ANAEMIAS 1st Dutch-Belgian meeting for patients and health professionals 21th -22th November 2015 Amsterdam The Netherlands The 6 th European Symposium on Rare Anaemias
More informationRisks and Benefits of Blood Transfusions. Objectives. Red Cells (Erythrocytes) Understand the following:
Risks and Benefits of Blood Transfusions Patient and Family Conference Aplastic Anemia & MDS International Foundation July 10-12 th, 2009 Indianapolis, Indiana Susan M. Carson RN, MSN, CPNP Childrens Hospital
More informationAnemia s. Troy Lund MSMS PhD MD
Anemia s Troy Lund MSMS PhD MD lundx072@umn.edu Hemoglobinopathy/Anemia IOM take home points. 1. How do we identify the condtion? Smear, CBC Solubility Test (SCD) 2. How does it present clincally? 3. How
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/35456 holds various files of this Leiden University dissertation. Author: Hassan, Suha Mustafa Title: Toward prevention of Hemoglobinopathies in Oman Issue
More informationMorbidities in Non-Transfusion-Dependent Thalassemias (NTDT)
Morbidities in Non-Transfusion-Dependent Thalassemias (NTDT) Thalassemia Intermedia: is disease morbidity as we know it today less severe than Thalassemia Major? Ali T. Taher, MD, PhD, FRCP Professor of
More informationField of Post-M.D. Training
TABLE C-1 (GRADUATES OF CANADIAN MEDICAL SCHOOLS) RANK Family Medicine Emergency Medicine (CFPC) Care of the Elderly (CFPC) Enhanced Skills: Other Fam. Med. Training FAMILY MEDICINE SUBTOTAL Anesthesiology
More informationEffects of monotherapy and combined therapy on LPI
Effects of monotherapy and combined therapy on LPI 14 12 DFO 40 mg/kg/day 14 12 Deferiprone 75 mg/kg/day 14 12 Deferiprone 75 mg/kg/day DFO 40 mg/kg/day DFO 40 mg/kg/day LPI (μm) 10 8 6 LPI (μm) 10 8 6
More informationPyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency Natural History Study Rachael Grace, MD, MMSc On behalf of the PKD NHS Investigators Assistant Professor, Harvard Medical School Director, Hematology Clinic, Boston Children
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationDisclosure. Presented analysis part of larger study funded by Terumo BCT
1 Comparison of Transfusion Adverse Events in Children with Sickle Cell Disease (SCD) Receiving or Automated Red Blood Cell Exchange (arbx) Transfusions for Stroke Prevention Shannon Kelly, M.D. 2 Disclosure
More informationBlood Transfusions in Children with Haemoglobinopathies
Blood Transfusions in Children with Haemoglobinopathies Version: 2 Date: 22 nd April 2010 Authors: Responsible committee or Director: Review date: Target audience: Stakeholders/ committees involved in
More informationGeneral Characterisctics
Anemia General Characterisctics Definition: anemia is a decrease in red blood cells. Happens due to underproduction, increased destruction or loss of red cells. Diagnosis of anemia: Hgb < 135 (men) Hgb
More informationDEFERASIROX IN THE TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN THALASSAEMIA MAJOR AND OTHER ANAEMIAS (April 2011)
DEFERASIROX IN THE TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN THALASSAEMIA MAJOR AND OTHER ANAEMIAS (April 2011) Version: Ratified by (name of Committee): Date ratified: Date issued: Expiry date: (Document
More informationPractical Management Of Osteoporosis
Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda
More informationTransfusion support in Thalassaemia. Dr.A.keerti 1 st year PG DEPT. OF TRANSFUSION MEDICINE
Transfusion support in Thalassaemia Dr.A.keerti 1 st year PG DEPT. OF TRANSFUSION MEDICINE Structure of hemoglobin Types of hemoglobins Hemoglobin-Development Switching Thalassaemia- introduction Classification
More informationExjade. Exjade (deferasirox) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.11.02 Subject: Exjade Page: 1 of 5 Last Review Date: December 5, 2014 Exjade Description Exjade (deferasirox)
More informationBisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
More informationNeonatal Screening for Genetic Blood Diseases. Shaikha Al-Arayyed, PhD* A Aziz Hamza, MD** Bema Sultan*** D. K. Shome, MRCPath**** J. P.
Bahrain Medical Bulletin, Vol. 29, No. 3, September, 2007 Neonatal Screening for Genetic Blood Diseases Shaikha Al-Arayyed, PhD* A Aziz Hamza, MD** Bema Sultan*** D. K. Shome, MRCPath**** J. P. Bapat,PhD****
More informationTransfusions in Sickle Cell Disease: How, When and Why
Transfusions in Sickle Cell Disease: How, When and Why James R. Eckman, MD Professor Emeritus of Hematology and Medical Oncology Emory University School of Medicine This work is supported by the Centers
More informationExjade q (deferasirox): Important information for patients about your treatment and possible side effects
Exjade q (deferasirox): Important information for patients about your treatment and possible side effects NAME DATE Please keep this document safe for future reference. This booklet is only intended for
More informationInternational Journal of Biological & Medical Research
Int J Biol Med Res.2015;6(1):4756-4761 Contents lists available at BioMedSciDirect Publications International Journal of Biological & Medical Research Journal homepage: www.biomedscidirect.com BioMedSciDirect
More informationNIH Public Access Author Manuscript Pediatr Blood Cancer. Author manuscript; available in PMC 2011 October 1.
NIH Public Access Author Manuscript Published in final edited form as: Pediatr Blood Cancer. 2010 October ; 55(4): 678 683. doi:10.1002/pbc.22565. Education and Employment Status of Children and Adults
More informationBridging the Gap: Improving Sickle Cell Disease Transition from Pediatric- to Adult-Focused Care ASFA 2017 Annual Meeting
Bridging the Gap: Improving Sickle Cell Disease Transition from Pediatric- to Adult-Focused Care ASFA 2017 Annual Meeting Kim Smith-Whitley, MD Director Comprehensive Sickle Cell Center The Children s
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationSickle Cell Disease. New Drug Therapies Anti-Adhesion Agents
Sickle Cell Disease New Drug Therapies Anti-Adhesion Agents Matthew M. Heeney, MD Associate Chief, Hematology Director, Sickle Cell Program Children s Hospital Boston ASCAT 10 th Academy for Sickle Cell
More informationOpinion 22 January 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 22 January 2014 EXJADE 125 mg, dispersible tablets B/28 (CIP 34009 376 951 1 4) B/84 (CIP 34009 376 952 8 2) EXJADE
More informationPresented at the 60th Annual Meeting of the American Society of Hematology (ASH); December 1 4, 2018; San Diego, CA, USA.
The BELIEVE Trial: Results of a Phase 3, Randomized, Double-Blind, -Controlled Study of in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions Maria Domenica Cappellini,
More informationParathyroid function in children with beta thalassemia and correlation with iron load
Parathyroid function in children with beta thalassemia and correlation with iron load Adel A. Hagag 1*, Mohamed R. El-Shanshory 1, Amany M. Abo El-Enein 2 1 Pediatric Department, Faculty of Medicine, Tanta
More informationExjade (tablets for oral suspension), Jadenu (deferasirox)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.99.02 Subject: Exjade Jadenu Page: 1 of 5 Last Review Date: December 2, 2016 Exjade Jadenu Description
More information6 th EUROPEAN SYMPOSIUM ON RARE ANAEMIAS 1 st Dutch-Belgian meeting for patients and health professionals
6 th EUROPEAN SYMPOSIUM ON RARE ANAEMIAS 1 st Dutch-Belgian meeting for patients and health professionals Dr. Marjon H. Cnossen, paediatric haematologist Erasmus MC-Sophia Children s Hospital, Rotterdam,
More informationHydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease
Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease A Pocket Guide for the Clinician Susan E. Creary, MD, MSc 1 John J. Strouse, MD, PhD 2 1 The Ohio State University School of
More information"Asymptomatic" Hyperparathyroidism: Reasons for Parathyroidectomy
"Asymptomatic" Hyperparathyroidism: Reasons for Parathyroidectomy Rebecca S. Sippel, M.D. Assistant Professor Department of Surgery Section of Endocrine Surgery University of Wisconsin Primary Hyperparathyroidism
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Exjade, Jadenu) Reference Number: CP.PHAR.145 Effective Date: 11.01.15 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end
More informationEvidence for the Safety of Fortifying Flour with Iron in the Presence of Thalassemia and Other Blood Disorders
Evidence for the Safety of Fortifying Flour with Iron in the Presence of Thalassemia and Other Blood Disorders Althea M Grant, PhD Chief, Epidemiology and Surveillance Branch, Division of Blood Disorders,
More informationThe Thalassemias in Clinical Practice. Ashutosh Lal, MD Director Comprehensive Thalassemia Program UCSF Benioff Children s Hospital Oakland
The Thalassemias in Clinical Practice Ashutosh Lal, MD Director Comprehensive Thalassemia Program UCSF Benioff Children s Hospital Oakland Outline Thalassemia: definitions and pathophysiology Epidemiology
More informationFerriScan provides an accurate assessment of body iron stores
FerriScan provides an accurate assessment of body iron stores A clinician s guide to managing transfusional iron overload with FerriScan Transfusional iron overload Patients receiving multiple blood transfusions
More informationSICKLE CELL DISEASE. Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH. Assistant Professor FACULTY OF MEDICINE -JAZAN
SICKLE CELL DISEASE Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN Objective: The student should be able: To identify the presentation, diagnosis,
More informationNewborn Screening for Sickle Cell Disease in Africa: Public health meets reality
13 th September 2016 Newborn Screening for Sickle Cell Disease in Africa: Public health meets reality Kwaku Ohene-Frempong. MD Children s Hospital of Philadelphia Sickle Cell Foundation of Ghana Disclosure
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationCURRENT RESEARCH STUDIES
CURRENT RESEARCH STUDIES SCAGO SICKLE CELL RESEARCH DAY MAY 12, 2018 REBECCA LEROUX RN, BSCN, CCRP RED BLOOD CELL DISORDERS PROGRAM, UNIVERSITY HEALTH NETWORK MANUELA MERELLES-PULCINI RN, BSCN, MSN, CCRP
More informationClass Update: Iron Chelators. Month/Year of Review: June 2015 Date of Last Review: June 2012
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationStudy on Safety and Efficacy of Deferasirox in the treatment of Thalassemia in a South Indian Tertiary Care Hospital
Research Article Study on Safety and Efficacy of Deferasirox in the treatment of Thalassemia in a South Indian Tertiary Care Hospital Siva Shankar Reddy Y *1, Umesh Kamrthi 2 and Balasubramanian Kumar
More information